Infectious diseases, caused by pathogenic micro organisms, such as bacteria, viruses, parasites or fungi, are responsible for millions of deaths globally each year. Vaccines are estimated to save millions of lives each year. In addition to eradicating two naturally occurring diseases, global vaccination has significantly reduced the incidence of many others (in many cases it is estimated by over 90%).
However, despite this track record of success, vaccination remains relatively underutilised.
Through our collaborations, we have focused on developing novel solid dose formulations of existing vaccines and exemplified the potential value of our ImplaVax® technology for improving vaccination by completing successful studies in several infectious diseases, including seasonal/pandemic influenza and diphtheria.
Potential dose and regimensparing were noted in all studies, with enhanced immune response seen compared to commercial vaccines, producing potentially protective antibody responses after a single dose of the ImplaVax® vaccine.
We expect that the use of ImplaVax® solid dose formulations will lead to an increased uptake in vaccination, due to this strong potential for regimen sparing (as one dose only can deliver both ‘Prime’ and ‘Booster’ inoculations) as well as the the strong patient preference for needle-free vaccination. In our first human factors study, we found that the ImplaVax® platform was preferred (93%) by all groups of administrators, recipients and parents in comparison to a standard needle and syringe injection.
Infectious disease – improved versions of existing vaccines
A public-private partnership* between Enesi and the U.S. Biomedical Advanced Research and Development Authority’s (BARDA) DRIVe (Division of Research, Innovation, and Ventures) initiative to develop new influenza vaccines enabled by ImplaVax® technology. DRIVe is an initiative of BARDA that supports the development of innovative products and approaches aiming to solve major health security challenges.
The partnership aims to generate evidence to support the use of solid dose presentations as the preferred method of vaccination in a future pandemic influenza event, with the potential of enhancing the immune response, while improving logistics (manufacture, stockpiling) and reducing storage and distribution costs.
*This project has been funded in whole or in part with US Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, DRIVe, under this contract.
Enesi has entered a collaboration with an undisclosed international partner to develop a solid dose version of the Typhoid Conjugate Vaccine, bringing improvements to the existing manufacturing and supply chain of the vaccine.
Enesi was awarded grant funding from the Bill & Melinda Gates Foundation* in October 2019 to evaluate the ImplaVax® technology for enabling the development and delivery of solid dose vaccines for Measles and Rubella. The project aims to generate compelling data to confirm if the ImplaVax platform can impart significant advantages to the delivery of vaccines for these diseases, such as bringing user improvements, enhancements to the existing manufacturing and supply chain of the vaccine, together with the potential for regimen sparing.
*’Bill & Melinda Gates Foundation’ is a registered trademark of the Bill & Melinda Gates Foundation in the United States and is used with permission.